The U.S. FDA has approved updated COVID-19 vaccines for 2024-2025, targeting the KP.2 strain which has been significantly contributing to rising infections this summer.
Due to rapid mutations, vaccine manufacturers had to shift focus to KP.2 variants to ensure ongoing effectiveness against the evolving strains of the virus.
Testing and manufacturing of vaccines takes additional time, which makes it challenging to keep up with rapidly mutating COVID-19 variants in real-time.
Despite the rapid mutations, vaccines targeting variants in the FLiRT group are likely to be effective against each other, albeit at different efficacy levels.
[
Collection
]
[
|
...
]